StemCells Inc (STEM)

0.40
0.03 6.30
NASDAQ : Health Care
Prev Close 0.43
Open 0.43
Day Low/High 0.40 / 0.48
52 Wk Low/High 0.33 / 7.56
Volume 1.07M
Avg Volume 673.10K
Exchange NASDAQ
Shares Outstanding 11.70M
Market Cap 4.21M
EPS -4.60
Div & Yield N.A. (N.A)

Latest News

StemCells, Inc. Presents Interim Results From Its Phase II Pathway Study In Chronic Cervical Spinal Cord Injury At ASIA Annual Meeting

StemCells, Inc. Presents Interim Results From Its Phase II Pathway Study In Chronic Cervical Spinal Cord Injury At ASIA Annual Meeting

Final Results for the First Six Patients to be Released Later this Quarter

StemCells, Inc. Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update

StemCells, Inc. Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update

Conference Call to be Hosted March 24, 2016, at 5:00 a.m. Pacific Daylight Time (8:00 a.m. Eastern Daylight Time)

StemCells, Inc. CEO Martin McGlynn Passes Baton To President And COO Ian Massey

StemCells, Inc. CEO Martin McGlynn Passes Baton To President And COO Ian Massey

Experienced Biotech Leader to Become Next Chief Executive Officer

StemCells, Inc. To Participate At The 8th Annual Biotech Showcase Investor Conference

StemCells, Inc. To Participate At The 8th Annual Biotech Showcase Investor Conference

Management Will Present an Update on the Company's Programs, Pipeline and Operations

StemCells, Inc. Announces Strategic Realignment

StemCells, Inc. Announces Strategic Realignment

Prioritizes Spinal Cord Injury Program to Reduce Cash Needs and Expedite Progress to Pivotal Data

StemCells, Inc. Interim Trial Data Show Motor Improvement In Patients With Cervical Spinal Cord Injury

StemCells, Inc. Interim Trial Data Show Motor Improvement In Patients With Cervical Spinal Cord Injury

Positive Six-Month Results, With Gains in Both Strength and Motor Function, for the First Cohort in the Phase II Pathway Study

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

StemCells, Inc. To Participate At The Rodman & Renshaw 17th Annual Global Investment Conference

StemCells, Inc. To Participate At The Rodman & Renshaw 17th Annual Global Investment Conference

Management Will Present an Update on the Company's Programs, Pipeline and Operations

StemCells, Inc. Reports Second Quarter 2015 Financial Results, Business Update And Clinical Program Highlights

StemCells, Inc. Reports Second Quarter 2015 Financial Results, Business Update And Clinical Program Highlights

Conference Call August 6, 2015, at 4:30 PM EDT (1:30 PM PDT) Including New Information About Phase I/II AMD Trial Results

StemCells, Inc. Transplants First Patient In Phase II Clinical Trial For Dry Age-Related Macular Degeneration

StemCells, Inc. Transplants First Patient In Phase II Clinical Trial For Dry Age-Related Macular Degeneration

Radiant(TM) Study is the First Controlled Phase II Trial to Investigate the Efficacy of Human Neural Stem Cells for the Treatment of Dry AMD

StemCells, Inc. Clinical Programs Overview And Progress Update

StemCells, Inc. Clinical Programs Overview And Progress Update

Video Available of Presentation Made to World-Leading Scientists and Clinicians at the International Society for Stem Cell Research (ISSCR)

StemCells, Inc. To Participate At Cantor Fitzgerald's Inaugural Healthcare Conference

StemCells, Inc. To Participate At Cantor Fitzgerald's Inaugural Healthcare Conference

Management Will Present an Update on the Company's Programs, Pipeline and Operations

StemCells, Inc. Reports Top Line Results For Its Phase I/II Study In Dry Age Related Macular Degeneration

StemCells, Inc. Reports Top Line Results For Its Phase I/II Study In Dry Age Related Macular Degeneration

Initiates Phase II Proof-of-Concept Radiant(TM) Study in AMD